PDF Print E-mail
Written by Emerging Issuer   
Friday | 10 November 2006
MIV Therapeutics Incorporated
 
MIV Therapeutics Inc.
SYMBOL: (OTCBB: MIVT)
 
 
 
Share Data
Authorized Outstanding
Date Shares Source Date Shares Source
01/14/05   80,000,000   10QSB    08/31/06   70,495,895   MGFS
 
MIV Therapeutics Inc.
1-8765 Ash Street
Vancouver, BC V6P 6T3
Canada

Phone: 604-301-9545
Fax: 604 301-9546

http://www.mivtherapeutics.com
 
 
MANAGEMENT TEAM
 
 
Dr. Mark Landy
President

Alan P. Lindsay
Chief Executive Officer and Director

Patrick A. McGowan
Executive Vice President, Chief Financial Officer, and Director

Arc Rajtar
Vice President, Operations

Tom Troczynski, Ph.D., PEng
Vice President, Coating Technologies

Dov V. Shimon, M.D.
Director and Chief Medical Officer

Daniel Savard, M.D.
FRP, Director
COMPANY PROFILE
 
MIV Therapeutics Inc. (OTCBB: MIVT) is an advanced stage, research and development company pursuing the commercialization of the next generation of fully biocompatible coatings for stents and other medical devices with the intent of providing healing solutions for cardiovascular disease and other conditions. In collaboration with the University of British Columbia (UBC), the Company has developed unique coating technologies that utilize Hydroxyapatite (HAp) for application on medical devices and drug delivery systems.

MIVT has a strategic alliance with the University of British Columbia (UBC), where it has licensed from the university worldwide rights to technologies for coating stents and other medical devices with HAp. This coating enhances the biocompatibility of implanted devices since it is a material that is found in the body as the main constituent of bone.

MIVT’s technology is considered to be suitable for broad applications in cardiovascular and non-vascular drug/device combination products. The Company’s goal is to continue on its path of success and diversify its portfolio to capitalize on these potential applications, accessing the $200 billion market of combination drug/device products.

MIVT’s current product portfolio encompasses the following preclinical development projects:

HAp-nano-film coating technology. The Company’s lead product in development is an HAp-coated coronary stent with a nano-film coating. HAp is naturally found in bone and tooth enamel and is rapidly integrated into the human body. As such, it may inhibit a variety of adverse and inflammatory reactions and potentially help reduce restenosis, a recurrence of CAD following angioplasty. It is also believed that HAp-coated cardiovascular stents will not trigger late adverse thrombogenic reactions.

Drug-eluting stents. The Company is expected to enter the drug-eluting stent market by using a thicker coating of HAp loaded with a suitable drug, i.e. anti-inflammatory. The technology has applications in cardiovascular and non-cardiovascular drug/device combination products, including peripheral stents, biodegradable implants, gene therapy, and delivery systems for release of chemotherapeutic agents.
 
BUSINESS SUMMARY
 
MIV Therapeutics Inc. is a research and development company pursuing the commercialization of the next generation of fully biocompatible coatings for stents and other medical devices with the intent of providing healing solutions for cardiovascular disease and other conditions. In collaboration with the University of British Columbia, the Company has developed unique coating technologies that utilize Hydroxyapatite for application on medical devices and drug delivery systems.
Last Updated ( Tuesday | 13 May 2008 )
 
< Prev   Next >

Login

Links